Cover Image
市場調查報告書

肺炎球菌疫苗的全球市場 - 2016∼2020年

Global Pneumococcal Vaccine Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 251966
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
肺炎球菌疫苗的全球市場 - 2016∼2020年 Global Pneumococcal Vaccine Market 2016-2020
出版日期: 2016年08月01日 內容資訊: 英文 82 Pages
簡介

肺炎球菌疫苗的全球市場預測在2016年到2020年這段期間,將以13.69%的年複合成長率 (CAGR) 持續成長。

本報告涵蓋肺炎球菌疫苗的全球市場,透過推動市場成長要素和市場課題,市場趨勢,以及市場競爭情形的詳細調查,來進行市場現狀分析以及2016年到2020年的未來預測。

第1章 摘要整理

第2章 本報告涵蓋範圍

  • 市場概要
  • 主要供應商產品

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 序論

  • 市場相關重要事項

第5章 肺炎球菌疫苗:概要

  • 疫苗核准流程

第6章 市場概況

  • 市場概要
  • 波特的五力分析
  • 各組成市場分類
  • PCV (肺炎球菌結合型疫苗)的全球市場
    • 市場概要
  • PPV (23價肺炎球菌疫苗)的全球市場
    • 市場概要

第7章 肺炎球菌疫苗的全球市場 - 各地區市場分類

  • 南北美洲地區的肺炎球菌疫苗市場
  • 歐洲·中東·非洲地區的肺炎球菌疫苗市場
  • 亞太地區的肺炎球菌疫苗市場

第8章 肺炎球菌疫苗的全球市場 - 成長推動因素

  • 編入NIP (國家定期疫苗接種計劃)
  • 涵蓋廣泛的血清型
  • 肺炎球菌疫苗相關的全球性行動計劃

第9章 推動市場成長要素帶來的影響

第10章 肺炎球菌疫苗的全球市場 - 課題

  • 不完全的疫苗接種率
  • 冷藏的需求
  • 疫苗開發的大風險與成本
  • 嚴格的法律規章指南

第11章 推動市場成長要素和市場課題帶來的影響

第12章 肺炎球菌疫苗的全球市場 - 趨勢

  • 行銷對象地區的擴大
  • 蛋白質抗原組合型肺炎球菌疫苗的出現
  • 肺炎球菌疫苗的AMC (疫苗事前買進制度)
  • 生物恐怖行動
  • 公私合營

第13章 業者情勢

  • 市場競爭方案
  • 重要新聞
  • Pfizer
  • Sanofi
  • GSK
  • Merck
  • 其他卓越供應商

第14章 附錄

第15章 關於Technavio

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR10147

About Pneumococcus

Pneumococcus (Streptococcus pneumoniae), a pathogenic bacterium, is the leading cause of serious illness worldwide. It is the major cause of pneumonia, blood infections, meningitis, sinusitis, and middle ear infections (otitis media). Pneumococcal infections affect children younger than five years and older people (65 years and older), and it is among the leading infectious disease. It kills almost 1.6 million people (including over 800,000 children under five years) every year. It can be prevented by vaccination and involves the introduction of a dead or weakened antigen into the human body. This produces lymphocytes to counter the infection and any future invasions by that antigen.

Technavio's analysts forecast the global pneumococcal vaccine market to grow at a CAGR of 13.69% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global pneumococcal vaccine market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of vaccines used to prevent pneumococcal infections.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Pneumococcal Vaccine Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • GlaxoSmithKline (GSK)
  • Merck
  • Pfizer
  • Sanofi

Other Prominent Vendors

  • Abera
  • AstraZeneca
  • Baxter
  • Beijing Minhai Biotechnology
  • Biken
  • Biogen
  • Celgene
  • Eli Lilly
  • Genentech
  • Genocea Biosciences
  • ImmunoBiology
  • Lupin
  • Nuron Biotech
  • Panacea Biotec (India)
  • S K Chemicals
  • Serum Institute of India
  • Sinovac
  • Valneva Austria

Market driver

  • Inclusion in NIP
  • For a full, detailed list, view our report

Market challenge

  • Inadequate vaccine coverage
  • For a full, detailed list, view our report

Market trend

  • Expansion of marketing territories
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Pneumococcal vaccine: Overview

  • Vaccine approval process

PART 06: Market landscape

  • Market overview
  • Five forces analysis
  • Market segmentation by composition
  • Global PCV market
  • Market overview
  • Global PPV market
  • Market overview

PART 07: Geographical segmentation

  • Pneumococcal vaccine market in Americas
  • Pneumococcal vaccine market in EMEA
  • Pneumococcal vaccines market in APAC

PART 08: Market drivers

  • Inclusion in NIP
  • Broad serotype coverage
  • Global action plans for pneumonia vaccines

PART 09: Impact of drivers

PART 10: Market challenges

  • Inadequate vaccine coverage
  • Require cold storage
  • High risk and cost involved in vaccine development
  • Stringent regulatory guidelines

PART 11: Impact of drivers and challenges

PART 12: Market trends

  • Expansion of marketing territories
  • Emergence of protein-based combination pneumococcal vaccines
  • AMC for pneumococcal vaccines
  • Bio-terrorism
  • Public-private initiatives

PART 13: Vendor landscape

  • Competitive scenario
  • Key news
  • Pfizer
  • Sanofi
  • GSK
  • Merck
  • Other prominent vendors

PART 14: Appendix

  • List of abbreviations

PART 15: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Market share of pneumococcus vaccine market in global pharmaceutical market 2015
  • Exhibit 03: Market share of pneumococcal vaccine markets in global pharmaceutical market, 2015
  • Exhibit 04: Global pneumococcal vaccine market snapshot
  • Exhibit 05: Milestones in pneumococcus vaccines development
  • Exhibit 06: Key buying criteria for pneumococcal vaccine 2015
  • Exhibit 07: Impact of key customer segments on market 2015
  • Exhibit 08: Requirements for a BLA submission
  • Exhibit 09: Types of development necessary to reach vaccine licensing stage
  • Exhibit 10: Vaccine development process over a period of up to 15 years at a cost of up to $1 billion
  • Exhibit 11: Regulatory testing of licensed vaccines
  • Exhibit 12: Economic burden of pneumococcal disease in children 2015
  • Exhibit 13: Total global costs for treating pneumococcal disease 2015 ($ billions)
  • Exhibit 14: Global pneumococcal vaccine market snapshot: Developed and emerging markets 2015
  • Exhibit 15: Overview of vaccine-related acquisitions 2005-2012
  • Exhibit 16: Global pneumococcal vaccine market 2015-2020 ($ billions)
  • Exhibit 17: Approved pneumococcal serotypes
  • Exhibit 18: Global pneumococcal vaccines market by volume 2013-2020 (million doses)
  • Exhibit 19: Impact of drivers and challenges on global pneumococcal vaccine market
  • Exhibit 20: Five forces analysis
  • Exhibit 21: Global pneumococcal vaccines market: Segmentation by composition 2015-2020
  • Exhibit 22: Global pneumococcal vaccines market segmentation by application 2015
  • Exhibit 23: Global pneumococcal vaccines market segmentation: Growth cycle analysis
  • Exhibit 24: Global supply and demand of PCV ($ millions) (2010-2017)
  • Exhibit 25: Price evolution of PCV (2009-2015)
  • Exhibit 26: Global PCV market 2015-2020 ($ billions)
  • Exhibit 27: Opportunity analysis of global conjugate vaccines market by composition
  • Exhibit 28: Global PPV market 2015-2020 ($ billions)
  • Exhibit 29: Opportunity analysis of global polysaccharide vaccines market by composition
  • Exhibit 30: Global PPV market segmentation by composition 2015
  • Exhibit 31: Global pneumococcal vaccine market by geography 2015
  • Exhibit 32: Global pneumococcal vaccine market: Geographical outlook (2015-2020)
  • Exhibit 33: Global pneumococcal vaccine market: Geographical outlook 2015
  • Exhibit 34: Segmentation of global pneumococcal vaccine market by region: Market growth lifecycle analysis 2015
  • Exhibit 35: Opportunity analysis of pneumococcal vaccine market in Americas
  • Exhibit 36: Pneumococcal vaccine market in Americas 2015-2020 ($ billions)
  • Exhibit 37: Pneumococcal vaccine market in Americas: PEST analysis
  • Exhibit 38: Opportunity analysis of pneumococcal vaccine market in EMEA
  • Exhibit 39: Pneumococcal vaccine market in EMEA 2015-2020 ($ billions)
  • Exhibit 40: Pneumococcal vaccine market in EMEA: PEST analysis
  • Exhibit 41: Opportunity analysis of pneumococcal vaccine market in APAC
  • Exhibit 42: Pneumococcal vaccine market in APAC 2015-2020 ($ billions)
  • Exhibit 43: Pneumococcal vaccine market in APAC: PEST analysis
  • Exhibit 44: Impact of drivers
  • Exhibit 45: A typical cold chain process
  • Exhibit 46: Impact of drivers and challenges
  • Exhibit 47: Global pneumococcal vaccines market: Impact assessment of key trends 2015
  • Exhibit 48: Developing countries and their approval status for GAVI support
  • Exhibit 49: Pneumococcal procurement volumes through AMC (million doses)
  • Exhibit 50: Geographical presence of top vendors in global pneumococcal vaccine market 2015
  • Exhibit 51: Competitive assessment of vendors
  • Exhibit 52: Key vendors: Geographical presence 2015
  • Exhibit 53: Pfizer: YoY revenue and growth rate of Prevnar 2013-2015 ($ billions)
  • Exhibit 54: Pfizer: Revenue forecast of Prevnar 2016-2020 ($ billions)
  • Exhibit 55: Pfizer: Metrics analysis
  • Exhibit 56: Sanofi: YoY revenue growth of Meningitis/pneumonia vaccines 2013-2015 ($ millions)
  • Exhibit 57: Geographical segmentation of meningitis vaccines/PCVs by revenue 2015
  • Exhibit 58: Sanofi: Metrics analysis
  • Exhibit 59: GSK: YoY revenue and growth rate of Synflorix 2013-2015 ($ millions)
  • Exhibit 60: GSK: YoY geographical revenue of Synflorix 2013-2015 ($ millions)
  • Exhibit 61: GSK: Geographical segmentation of Synflorix 2015
  • Exhibit 62: Synflorix price per dose in different countries
  • Exhibit 63: GSK: Metrics analysis
  • Exhibit 64: Merck: YoY revenue growth of Pneumovax 23 2013-2015 ($ millions)
  • Exhibit 65: Merck: Metrics analysis
Back to Top